Key facts
- It has raised $340K; the latest was Angel (individual) in May 2025.
- Notable investors include Berkeley SkyDeck, Cambridge Angels, Accelerate Cambridge, Cancer Tech Accelerator, Cariplo Factory — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Cambridge Nucleomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cambridge Nucleomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cambridge Nucleomics
Developer of a biotechnology platform designed to enable fast and direct quantification of native RNA molecules. The company's platform digitizes RNA measurement with single-molecule accuracy, providing high-multiplexed, enzyme-free detection that enhances RNA quantification, diagnostics, and drug discovery, enabling pharmaceutical and clinical researchers to achieve precise and scalable insights for personalized medicine.
- Sector
- Healthcare
- HQ
- Rutland, United Kingdom
- Founded
- 2021
- Employees
- 7
- Website
- cambridge-nucleomics.com/
- Ownership
- Privately Held (backing)
Cambridge Nucleomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambridge Nucleomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambridge Nucleomics in its N-PORT filings yet. We sweep new filings monthly.